• Users Online: 1142
  • Home
  • Print this page
  • Email this page

 Table of Contents  
Year : 2016  |  Volume : 5  |  Issue : 5  |  Page : 62-63

Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience

1 Republican Scientific and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus
2 Global Tuberculosis Programme, World Health Organisation, Geneva, Switzerland
3 General Directorate of Medical Care, Ministry of Health, Minsk, Belarus
4 Country Office, World Health Organisation, Minsk, Belarus
5 Regional Office for Europe, World Health Organisation, Copenhagen, Denmark
6 Centre for Examinations and Tests in Health Care, Minsk, Belarus

Date of Web Publication17-Feb-2017

Correspondence Address:
Alena Skrahina
Republican Scientific and Practical Centre for Pulmonology and Tuberculosis, Minsk
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.1016/j.ijmyco.2016.11.014

Rights and Permissions

Background/objective: Outcomes of treatment for multidrug-resistant tuberculosis (MDR-TB) remain poor worldwide. Among patients with MDR-TB in Belarus who started treatment in 2012, only 54% completed it successfully, with treatment failure reported in 22% of the patients; additionally, 11% died and 13% were lost to follow-up or remained unevaluated. In Belarus, to improve outcomes, bedaquiline was introduced in MDR-TB treatment in June 2015. The national TB program developed measures to monitor safety and effectiveness of bedaquiline-containing regimens in line with the World Health Organization recommendations.
Methods: After enrollment of patients, clinical, radiological, laboratory, and microbiological data were carefully collected at start, during treatment, and at follow-up. A total of 197 patients were enrolled: male, 140 (71%); female, 57 (29%); new TB cases, 83 (42%); previously treated, 114 (58%); extensively drug-resistant-TB (XDR-TB), 128 (65%), pre-XDR-TB (fluoroquinolone resistant), 34 (17%), pre-XDR-TB (injectables resistant), 25 (13%), and other MDR-TB cases, 10 (5%).
Results: According to the intermediate analysis, 186 patients currently are continuing with the treatment, two patients died, and nine patients were lost to follow-up. Sputum culture conversion were observed in 186 patients (94%) at 6 months and one (0.5%) of these 197 patients started treatment; six patients (3%) remain sputum culture positive. The safety data were as follows: 135 patients (68%) experienced metabolism and nutrition disorders (hyperuricemia being the most common), 127 patients (64%) experienced hepatobiliary disorders (hepatic functions abnormality being the most common), 93 patients (47%) experienced electrolyte disorders (hypomagnesemia being the most common), 80 patients (41%) experienced cardiac disorders (abnormal electrocardiogram and arrhythmia being the most common), 68 patients (35%) experienced gastrointestinal system disorders (nausea, vomiting, and abdominal pain being the most common disorders), 54 patients (27%) experienced blood and the lymphatic system disorders (low platelet count being the most common), 42 patients (21%) experienced renal and urinary disorders (creatinine clearance decrease being the most common), 40 patients (20%) experienced nervous system disorders (headache, dizziness, and paresthesia being the most common ones), 36 patients (18%) experienced skin and subcutaneous tissue disorders (rush and pruritus being the most common), 35 patients (17%) experienced ear and labyrinth disorders (tinnitus and decreased hearing being the most common ones), 32 patients (15%) experienced psychiatric disorders (insomnia being the most common disorder), and 30 patients (14%) experienced infections and infestations (candidiasis being the most common). The most adverse events were mild or moderate in severity and reversible. One death was possibly related to MDR-TB therapy.
Conclusion: Our interim results on safety and effectiveness of bedaquiline-containing regimens in multidrug and extensively drug-resistant tuberculosis (M/XDR-TB) patients are encouraging. They will add value to understanding role and place of this new anti-TB drug in M/XDR-TB treatment.

Keywords: Anti-TB drug, Bedaquiline, Multidrug and extensively drug-resistant tuberculosis, Multidrug-resistant tuberculosis

How to cite this article:
Skrahina A, Hurevich H, Falzon D, Zhilevich L, Rusovich V, Dara M, Setkina S. Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience. Int J Mycobacteriol 2016;5, Suppl S1:62-3

How to cite this URL:
Skrahina A, Hurevich H, Falzon D, Zhilevich L, Rusovich V, Dara M, Setkina S. Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience. Int J Mycobacteriol [serial online] 2016 [cited 2023 Jan 28];5, Suppl S1:62-3. Available from: https://www.ijmyco.org/text.asp?2016/5/5/62/200488

  Conflicts of interest Top

The authors have no conflicts of interest to declare.

This article has been cited by
1 Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country
Dumitru Chesov,Jan Heyckendorf,Sofia Alexandru,Ana Donica,Elena Chesov,Maja Reimann,Valeriu Crudu,Victor Botnaru,Christoph Lange
European Respiratory Journal. 2021; 57(6): 2002544
[Pubmed] | [DOI]
2 Optima TB: A tool to help optimally allocate tuberculosis spending
Lara Goscé, Gerard J. Abou Jaoude, David J. Kedziora, Clemens Benedikt, Azfar Hussain, Sarah Jarvis, Alena Skrahina, Dzmitry Klimuk, Henadz Hurevich, Feng Zhao, Nicole Fraser-Hurt, Nejma Cheikh, Marelize Gorgens, David J. Wilson, Romesh Abeysuriya, Rowan Martin-Hughes, Sherrie L. Kelly, Anna Roberts, Robyn M. Stuart, Tom Palmer, Jasmina Panovska-Griffiths, Cliff C. Kerr, David P. Wilson, Hassan Haghparast-Bidgoli, Jolene Skordis, Ibrahim Abubakar, Roger Dimitri Kouyos
PLOS Computational Biology. 2021; 17(9): e1009255
[Pubmed] | [DOI]
3 Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
Francesco Pecora,Giulia Dal Canto,Piero Veronese,Susanna Esposito
Microorganisms. 2021; 9(5): 1074
[Pubmed] | [DOI]
4 Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China
Abela Mpobela Agnarson,Xiao Chun Wang,Ravi Potluri,Hitesh Bhandari,Amit Dhir,Chrispin Kambili,Laurent Metz
BMC Infectious Diseases. 2020; 20(1)
[Pubmed] | [DOI]
5 Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician’s perspective
Lorenzo Guglielmetti,Sheila Chiesi,Johannes Eimer,Jose Dominguez,Tiziana Masini,Francis Varaine,Nicolas Veziris,Florence Ader,Jérôme Robert
Future Microbiology. 2020;
[Pubmed] | [DOI]
6 The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa
Abela Mpobela Agnarson,Abeda Williams,Chrispin Kambili,Gunnar Mattson,Laurent Metz
Expert Review of Anti-infective Therapy. 2020; : 1
[Pubmed] | [DOI]
7 Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences
Edine Tiemersma,Susan van den Hof,Gunta Dravniece,Fraser Wares,Yohannes Molla,Yusie Permata,Endang Lukitosari,Mamel Quelapio,Si Thu Aung,Khay Mar Aung,Hoang Thanh Thuy,Vu Dinh Hoa,Merkinai Sulaimanova,Saadat Sagyndikova,Mavluda Makhmudova,Alijon Soliev,Michael Kimerling
European Respiratory Review. 2019; 28(153): 180115
[Pubmed] | [DOI]
8 Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
Lawrence Mbuagbaw,Lorenzo Guglielmetti,Catherine Hewison,Nyasha Bakare,Mathieu Bastard,Eric Caumes,Mathilde Fréchet-Jachym,Jérôme Robert,Nicolas Veziris,Naira Khachatryan,Tinatin Kotrikadze,Armen Hayrapetyan,Zaza Avaliani,Holger J. Schünemann,Christian Lienhardt
Emerging Infectious Diseases. 2019; 25(5)
[Pubmed] | [DOI]
9 Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging
Yang Li,Feng Sun,Wenhong Zhang
Drug Development Research. 2018;
[Pubmed] | [DOI]
10 New drugs and regimens for tuberculosis
Kwok-Chiu Chang,Eric Nuermberger,Giovanni Sotgiu,Chi-Chiu Leung
Respirology. 2018;
[Pubmed] | [DOI]
11 Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline
Emanuele Pontali,Lia DæAmbrosio,Rosella Centis,Giovanni Sotgiu,Giovanni Battista Migliori
European Respiratory Journal. 2017; 49(3): 1700146
[Pubmed] | [DOI]
12 Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?
Lorenzo Guglielmetti
European Respiratory Journal. 2017; 49(5): 1700738
[Pubmed] | [DOI]
13 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis
Ioana D. Olaru,Jan Heyckendorf,Sönke Andres,Barbara Kalsdorf,Christoph Lange
European Respiratory Journal. 2017; 49(5): 1700742
[Pubmed] | [DOI]
14 Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis
Priya Singh,Rashmi Kumari,Rup Lal
Indian Journal of Microbiology. 2017;
[Pubmed] | [DOI]
15 Bedaquiline
Reactions Weekly. 2017; 1643(1): 52
[Pubmed] | [DOI]


Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  In this article
Conflicts of int...

 Article Access Statistics
    PDF Downloaded176    
    Comments [Add]    
    Cited by others 15    

Recommend this journal